Navigation Links
Progeria: Promising results from new gene therapy on animals
Date:10/27/2011

t aimed to slow down the development of the disease, it did not reduce the quantities of progerin. To study this aspect, researchers needed to obtain a relevant animal model.

An "authentic" Progeria model

To generate a model of this kind, Spanish and French researchers decided to introduce a gene mutation (G609G), equivalent to that identified in humans (G608G), in mice to reproduce the exact pathological mechanism found in the children, with a view to then blocking it. The mice models were created under the supervision of Bernard Malissen using the IBISA platform located at the Marseille-Luminy Centre of Immunology . This approach made it possible to obtain young mice that produced progerin, characteristic of the disease in humans. After three weeks alive, the mutated mice displayed growth defects, weight loss caused by bone deformation and cardiovascular and metabolic anomalies mirroring the human phenotype and considerably reducing their lifespan (an average of 103 days compared with two years for wild mice). The progerin thus produced accumulates in mouse cells via genetic mechanisms (abnormal splicing) identical to those observed in humans, i.e. the source of anomalies characteristic of the disease.

for a targeted gene therapy

Using this unique Progeria animal model, the researchers focussed their efforts on implementing a mutation-targeted treatment, with a view to reducing, and, if possible, preventing the production of progerin. To this end, they used "vivo-morpholino" antisense oligonucleotide technology. "This technology, explains Nicolas Lvy, is based on introducing a synthetic antisense aglionecleotide into mice. As is the case with progeria, this sequence is applied to block (or facilitate) the production of a functional protein using a gene. In this case, the production of progerin, as well as lamin A from the gene, were reduced."

There was a highly significant increase in life expectancy
'/>"/>

Contact: Priscille Rivire
presse@inserm.fr
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. New method of growing high-quality graphene promising for next-gen technology
2. Study finds promising drug treatment for improving language, social function in people with autism
3. Cardiotrophin 1 shows promising results for treatment of obesity and metabolic syndrome
4. Researcher tests promising drug on those with Down syndrome
5. Exonhit and BGI announce successful completion of a promising next-generation sequencing project
6. Grants awarded to help bring promising bioscience discoveries to market
7. Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy
8. 22 of Americas most promising scientists selected as 2011 Pew Scholars in the Biomedical Sciences
9. A promising new approach to autoimmune diseases
10. Several abstracts on gout reveal true burden of disease and highlight promising new treatments
11. Celiac disease vaccine shows promising results in Phase I trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... professor and his doctoral student have designed a device ... collected from fog and dew., The device could provide ... around the globe., Cheng Luo, professor in the Mechanical ... in the same College of Engineering department, published "Bioinspired ... ACS, (American Chemical Society) Applied Materials & ...
(Date:9/17/2014)... Evolution and Yale University offers compelling support for the ... partially predict the likelihood of being diagnosed with mental ... life. The study analyzed medical records of 1.75 million ... 30 years, and adjusted for almost all other known ... Proceedings of the Royal Society, London B . ...
(Date:9/17/2014)... UTSouthwestern Medical Center have found that the most common ... helps repair the lining of blood vessels. Individuals with ... of this repair, putting them at higher risk for ... one mechanism by which apoE3 promotes a healthy cardiovascular ... said Dr. Philip Shaul , Professor of Pediatrics ...
Breaking Biology News(10 mins):Shorebird's beak inspires UT Arlington research on water collection 2Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Protein variant may boost cardiovascular risk by hindering blood vessel repair 2
... codes of over 40,000 women -- including those ... disease – has uncovered five common genetic variants that ... a paper published online today in the journal Nature, ... association study report that these five genes code for ...
... of the Health Sciences (USU) suggests that it may ... the myriad strains of the HIV virus. HIV is ... stimulate the body to produce cross-reactive antibodies that will ... of truly broad-spectrum neutralizing antibodies may be an achievable ...
... disease typically characterized by the slow but progressive onset ... about five years after diagnosis. However, according to a ... PLoS ONE, a subset of patients with a specific ... complete pulmonary failure and death without a lung transplant. ...
Cached Biology News:First confirmed common genetic risk factors for breast cancer 2Gene expression patterns predict rapid decline in idiopathic pulmonary fibrosis patients 2
(Date:9/17/2014)... Rockville, MD (PRWEB) September 17, 2014 ... Small Business Innovation Research (SBIR) grant to support the ... award will provide ITI with approximately $255,000 over one ... a leading cause of food allergy, affect over one ... anaphylaxis behind peanut allergy. Tree nut exposure is also ...
(Date:9/17/2014)... , Sept. 17, 2014 Intarcia Therapeutics, ... data from a study of the cost and predictability ... 50 th Annual Meeting of the European Association ... session today, Christian Frois , Ph.D., of Analysis ... series of planned Intarcia-sponsored, retrospective studies to characterize the ...
(Date:9/17/2014)... LAUDERDALE, Fla. , Sept. 17, 2014 Alternative ... an agreement to form a Special Purpose Vehicle in partnership ... based Jatropha centric agro energy company. The SPV shall be ... registered entity with AFAI as majority shareholder. The SPV shall ... Africa , particularly Ethiopia . ...
(Date:9/17/2014)... FRANCISCO, Calif. , Sept. 17, 2014 ... a molecular diagnostics company pioneering the field of molecular ... to chief operating officer. Mr. Hall joined ... the company,s commercial entry into endocrinology. Since 2012, he ... as well as managed care and billing functions. As ...
Breaking Biology Technology:Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
... slogans and catchy buzz-phrases to capture the media spotlight as ... equals broadband connectivity (EDEBC) is one of those slogans. ... the test of time. Otherwise, it fades faster than the ... EDEBC is becoming very proven because future economic viability is ...
... advice and $25,000 in cash prizes will be at ... 2007 Northeast Wisconsin Business Plan Contest . , ... existing businesses that are changing direction, in northeastern Wisconsin. ... place reward, entrepreneurs will receive advice about crafting their ...
... - An early-stage company developing diagnostics to test for kidney ... investments to secure federal clearance for its first clinical product. ... of $3.2 million since its inception in 1999, will use ... research and development activities. ,The round was led by Appleton-based ...
Cached Biology Technology:Locations must have connectivity to be viable 2Locations must have connectivity to be viable 3Locations must have connectivity to be viable 4Renovar captures $1.2M for product development 2
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... mounted on coated slides. Sections are large ...
... microarrays are derived from frozen embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... microarrays are derived from Paraffin embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... are derived from frozen embedded tissue blocks, ... procedures to ensure the highest quality. Tissues ... one block, sectioned at a thickness of ... are large (3-5mm in diameter) in comparison ...
Biology Products: